Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jennifer Hockings"'
Autor:
Ken B. Johnson, Anukriti Sharma, N. Lynn Henry, Mei Wei, Bihua Bie, Courtney E. Hershberger, Emily E. Rhoades, Alper Sen, Ryan E. Johnson, Jacob Steenblik, Jennifer Hockings, G. Thomas Budd, Charis Eng, Joseph Foss, Daniel M. Rotroff
Publikováno v:
Frontiers in Pain Research, Vol 4 (2023)
Taxanes, particularly paclitaxel and docetaxel, are chemotherapeutic agents commonly used to treat breast cancers. A frequent side effect is chemotherapy-induced peripheral neuropathy (CIPN) that occurs in up to 70% of all treated patients and impact
Externí odkaz:
https://doaj.org/article/fa59deaa118c42afa6c4f61aa2423303
Autor:
Shreya Louis, Robyn M. Busch, Dennis Lal, Jennifer Hockings, Olivia Hogue, Marcia Morita-Sherman, Deborah Vegh, Imad Najm, Chaitali Ghosh, Peter Bazeley, Charis Eng, Lara Jehi, Daniel M. Rotroff
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
ObjectiveSeizure outcomes after brain surgery for drug-resistant epilepsy (DRE) are very heterogeneous and difficult to predict with models utilizing the current clinical, imaging, and electrophysiological variables. In this pilot study, we investiga
Externí odkaz:
https://doaj.org/article/0923aa6f1e3e456bb3380cdefb1c553a
Autor:
Anukriti Sharma PhD, Ken B. Johnson MD, Bihua Bie MD, PhD, Emily E. Rhoades PhD, Alper Sen MD, Yuri Kida MS, Jennifer Hockings PharmD, PhD, Alycia Gatta BS, Jacqueline Davenport MS, Connie Arcangelini BS, Jennifer Ritzu BS, Jennifer DeVecchio BS, Ron Hughen BS, Mei Wei MD, G. Thomas Budd MD, N. Lynn Henry MD, Charis Eng MD, PhD, Joseph Foss MD, Daniel M. Rotroff PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 21 (2022)
Introduction: Taxanes are a class of chemotherapeutics commonly used to treat various solid tumors, including breast and ovarian cancers. Taxane-induced peripheral neuropathy (TIPN) occurs in up to 70% of patients, impacting quality of life both duri
Externí odkaz:
https://doaj.org/article/2f61e6efc01a47469603cde26a8719e5
Autor:
Chuang Liu, Junfei Zhao, Weiqiang Lu, Yao Dai, Jennifer Hockings, Yadi Zhou, Ruth Nussinov, Charis Eng, Feixiong Cheng
Publikováno v:
PLoS Computational Biology, Vol 16, Iss 2, p e1007701 (2020)
Tumor-specific genomic alterations allow systematic identification of genetic interactions that promote tumorigenesis and tumor vulnerabilities, offering novel strategies for development of targeted therapies for individual patients. We develop an In
Externí odkaz:
https://doaj.org/article/2f2cba8bf9d540278cdbc4739978b35f
Autor:
Eric Herber, Anna Bondar, Jennifer Hockings, Taylor Hermiller, Giavanna Russo-Alvarez, Lu Wang, Lauren Schulz
Publikováno v:
Journal of the American Pharmacists Association.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a5bb0ebb49beb21ef9f99142687f227
https://doi.org/10.1016/j.japh.2023.04.021
https://doi.org/10.1016/j.japh.2023.04.021
Publikováno v:
Hum Mol Genet
An individual’s inherited genetic makeup and acquired genomic variants may account for a significant portion of observable variability in therapy efficacy and toxicity. Pharmacogenomics (PGx) is the concept that treatments can be modified to accoun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1c04a27bddbdccc9be667bf346cfe3
https://pubmed.ncbi.nlm.nih.gov/32601683
https://pubmed.ncbi.nlm.nih.gov/32601683
Autor:
Angelika L. Erwin, Amy L. Pasternak, J. Kevin Hicks, Jennifer Hockings, Charis Eng, Neil Thomas Mason
Publikováno v:
Cleveland Clinic journal of medicine. 87(2)
Pharmacogenomics, ie, the study of how an individual’s genomic profile influences his or her response to drugs, has emerged as a clinical tool to optimize drug therapy. Certain variants in some genes increase the risk of severe, life-threatening ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0affb6d7aad64a6222c554ab1fecc3
https://pubmed.ncbi.nlm.nih.gov/32015054
https://pubmed.ncbi.nlm.nih.gov/32015054
Autor:
Yadi Zhou, Feixiong Cheng, Junfei Zhao, Ruth Nussinov, Weiqiang Lu, Chuang Liu, Jennifer Hockings, Yao Dai, Charis Eng
Publikováno v:
PLoS Computational Biology
PLoS Computational Biology, Vol 16, Iss 2, p e1007701 (2020)
PLoS Computational Biology, Vol 16, Iss 2, p e1007701 (2020)
Tumor-specific genomic alterations allow systematic identification of genetic interactions that promote tumorigenesis and tumor vulnerabilities, offering novel strategies for development of targeted therapies for individual patients. We develop an In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49c179312b89b252fd140a0b3877da37
http://europepmc.org/articles/PMC7062285
http://europepmc.org/articles/PMC7062285
Publikováno v:
Biochimica et biophysica acta. 1859(2)
kRAS is one of the most prevalent oncogenic aberrations. It is either upregulated or mutationally activated in a multitude of cancers, including pancreatic, lung, and colon cancers. While a significant effort has been made to develop drugs that targe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca062bd79773b2f9ead37c0f986708ce
https://pubmed.ncbi.nlm.nih.gov/26597160
https://pubmed.ncbi.nlm.nih.gov/26597160
Autor:
Jennifer Hockings, Tracy A. Brooks
Publikováno v:
Molecular Cancer Research. 12:A44-A44
kRAS is one of, if not the, most prevalent oncogenic aberrations identified to date, and has been well validated as a therapeutic target. It is either upregulated or mutationally activated in ∼30% of all cancers, including 60-90% of pancreatic canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42b7b52ec2ab9c0b291c07653ff34b62
https://doi.org/10.1158/1557-3125.rasonc14-a44
https://doi.org/10.1158/1557-3125.rasonc14-a44